EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome

EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome

Freienbach -- EffRx Pharmaceuticals SA, a specialty pharmaceutical company, today announced that the U.S. Food and Drug...
EffRx Signs Binosto® Distribution Agreements in Russia and Africa

EffRx Signs Binosto® Distribution Agreements in Russia and Africa

New Partnerships Significantly Expand Global Footprint for Proprietary Buffered Effervescent Osteoporosis Therapy
EffRx Pharmaceuticals and Kadmon Corporation Announce Global Collaboration

EffRx Pharmaceuticals and Kadmon Corporation Announce Global Collaboration

Zurich and New York, March 18, 2014 – EffRx Pharmaceuticals SA, a leader in innovative drug delivery technologies that improve...
 

Dedicated to Improving Patient Outcome and Quality of Life

EffRx Pharmaceuticals SA is an innovative specialty pharmaceutical company focused on the development of novel therapeutic entities for a variety of orphan and specialty indications.


© 2014 EffRx Pharmaceuticals